We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
André Overmeyer is head of the strategy and operational excellence group within Merck Serono technical operations. Previously, he led the expansion of the Merck Serono Biotech Center in Corsier-sur-Vevey, Switzerland.
1. Pfizer US pharmaceutical giant Pfizer maintained its top position in 2011 with stipulated revenue of $67.4bn, up by 1% compared with $67.1bn in 2010. The company’s new
A total of 40% of respondents from the global pharmaceutical industry stated that they anticipated an increase in sustainability budgets.
World Pharmaceutical Frontiers presents the most influential people in the pharmaceuticals and biotechnology industry.|Dr Janet Woodcock.|Sir Andrew Witty.|Margaret Hamburg.|David Cameron.|Eric Lander.|Sir Paul Nurse.
The pharmaceutical industry, particularly in North America, has recorded major M&As and asset transactions.
‘Front door’ risks include inadequate personnel background checking prior to hiring individuals who will have access to technology.
All organisations taking part in IMI projects will gain from access to pre-competitive information and data, being creatively stimulated by collaborating with key partners in other sectors.|Michael Goldman is executive director of the IMI. In 2004, he established the IMI as the first biomedical public-private partnership in Wallonia, Belgium. He is also vice-president of the BioWin Health Cluster, which fosters networks between industries and academic institutions in the region.
Figure 1: co-crystal formation.|Figure 2: comparison of itraconazole by current and SFCC technology.
Susan Howard has worked in the pharmaceutical industry for 18 years with GSK. She took a contractor position for a year to take a break from nursing and stayed. Howard is a global compound lead in oncology data management and has worked with EDC since 1999.
Hugh Pullen is associate director of European government affairs for Eli Lilly. He covers anti-counterfeiting issues and is vice-chair of the Anti-Counterfeiting Working Group of the European Federation of Pharmaceutical Industries and Associations.